NOV 5

Rare Disease Clinical Trials: Challenges and Opportunities presented by Dr. Emily Morris, FDA Office of Biostatistics CDER

Collecting and Applying Evidence to Interpret Clinical Outcome Assessments (COA)-based Endpoints in
Clinical Trials presented by Dr. Weimeng Wang, FDA Office of Biostatistics CDER

Break

Panel Discussion